Heungkuk Securities
Seoul, Seoulheungkuksec.co.kr
Overview
Heungkuk Securities is a South Korean securities company and a member of the Taekwang Group. Its main business includes investment brokerage, trading, underwriting of debt securities, and investment banking (IB) services such as advisory for project financing and real estate. It also provides stock brokerage and sells financial products to institutional and corporate clients. The firm is known to participate in direct investments, such as its role in the Series B funding for Avelos Therapeutics.
Portfolio Companies
5
Website
heungkuksec.co.krInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| DewCell Inc. | Sep 2024 | Series B | Co-investor |
| ArtBlood | Sep 2024 | Series A | Co-investor |
| Avelos Therapeutics | Apr 2024 | Series B | Co-investor |
| ArtBlood | Apr 2024 | Series A | Co-investor |
| Daan Biotherapeutics | Jan 2024 | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
